Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CytoDyn Inc.CYDY · Entity 5856 | See Remarks | January 06, 2020 | January 09, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CytoDyn Inc.
Report date January 06, 2020 · Filed January 09, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.98 · Expires 2030-01-06 | Direct | 200,000 |
Reported balance
After 2020-01-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-01-06 · Grant · Acquired 200,000 · Balance 200,000 F1: The options will vest in three equal annual installments over a three-year period, with the first installment vesting on January 6, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: The options will vest in three equal annual installments over a three-year period, with the first installment vesting on January 6, 2021.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 06, 2020 Filed Jan 9, 2020 01:31 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantStock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $0.98 | $0.00 |
DisclosureSEC source: 0000899243-20-000852 · doc4.xml · derivative · entry 1 Fleming Maura · CIK 0001798921 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2030-01-06 F1 · derivative.exercise_date: The options will vest in three equal annual installments over a three-year period, with the first installment vesting on January 6, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.